Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome-Reference-Cited by-同舟云学术

Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome

Published:2021-11-18 Issue: Volume: Page:
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Shoucair Sami,Habib Joseph R.,Pu Ning,Kinny-Köster Benedict,van Ooston A. Floortje,Javed Ammar A.,Lafaro Kelly J.,He Jin,Wolfgang Christopher L.,Yu Jun

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-021-11081-z.pdf

Reference38 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.

2. Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16(1):11–26. https://doi.org/10.1038/s41571-018-0112-1.

3. Conroy T, Hammel P, Hebbar M, et al. Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406. https://doi.org/10.1056/nejmoa1809775.

4. Kinny-Köster B, van Oosten F, Habib JR, et al. Mesoportal bypass, interposition graft, and mesocaval shunt: surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer. Surgery. 2020;168(6):1048–55. https://doi.org/10.1016/j.surg.2020.07.054.

5. Habib JR, Kinny-Köster B, vanOosten F, et al. Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: surgical planning with the “halo sign” and “string sign.” Surgery. 2020. https://doi.org/10.1016/j.surg.2020.08.031.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer;Cancer Cell;2024-09

2. KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways;Cells;2024-07-19

3. Sex Matters–Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer;Cancers;2024-05-16

4. The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma;Journal of Clinical Medicine;2024-04-04

5. Prognostic utility of TME-associated genes in pancreatic cancer;Frontiers in Genetics;2023-09-01